Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERNA NASDAQ:PHXM NASDAQ:SLRX NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAErnexa Therapeutics$1.31+3.6%$1.69$1.19▼$23.70$10.06M5.65285,676 shs58,844 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASLRXSalarius Pharmaceuticals$4.65+0.1%$8.58$4.50▼$108.00$2.37M0.51146,611 shs10,433 shsTLPHTalphera$0.83-2.6%$0.48$0.38▼$1.19$17.28M-0.16980,812 shs437,951 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAErnexa Therapeutics+2.02%-5.60%-25.59%-46.79%-94.56%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SLRXSalarius Pharmaceuticals-0.22%-6.64%-38.13%-59.30%-79.51%TLPHTalphera+4.15%+57.96%+108.30%+66.28%-17.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAErnexa Therapeutics$1.31+3.6%$1.69$1.19▼$23.70$10.06M5.65285,676 shs58,844 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ASLRXSalarius Pharmaceuticals$4.65+0.1%$8.58$4.50▼$108.00$2.37M0.51146,611 shs10,433 shsTLPHTalphera$0.83-2.6%$0.48$0.38▼$1.19$17.28M-0.16980,812 shs437,951 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAErnexa Therapeutics+2.02%-5.60%-25.59%-46.79%-94.56%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%SLRXSalarius Pharmaceuticals-0.22%-6.64%-38.13%-59.30%-79.51%TLPHTalphera+4.15%+57.96%+108.30%+66.28%-17.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERNAErnexa Therapeutics 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ASLRXSalarius Pharmaceuticals 0.00N/AN/AN/ATLPHTalphera 3.50Strong Buy$5.00501.68% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERNAErnexa Therapeutics$580K17.32N/AN/A$0.50 per share2.62PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/A$14.31 per shareN/ATLPHTalphera$650K26.23N/AN/A$0.47 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-682.08%11/10/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals-$5.58M-$43.48N/A∞N/AN/A-556.47%-192.35%11/12/2025 (Estimated)TLPHTalphera-$13M-$0.40N/AN/AN/AN/A-152.38%-64.32%11/12/2025 (Estimated)Latest SLRX, TLPH, ERNA, and PHXM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TLPHTalphera-$0.1150-$0.10+$0.0150-$0.10N/AN/A8/13/2025Q2 2025ERNAErnexa TherapeuticsN/A-$0.61N/A-$0.61N/AN/A8/12/2025Q2 2025SLRXSalarius Pharmaceuticals-$33.00-$0.45+$32.55-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERNAErnexa TherapeuticsN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERNAErnexa TherapeuticsN/A1.811.81PHXMPHAXIAM Therapeutics0.231.78N/ASLRXSalarius PharmaceuticalsN/A0.610.61TLPHTalpheraN/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERNAErnexa Therapeutics70.55%PHXMPHAXIAM Therapeutics0.40%SLRXSalarius Pharmaceuticals11.88%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipERNAErnexa Therapeutics4.49%PHXMPHAXIAM Therapeutics1.94%SLRXSalarius Pharmaceuticals1.20%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERNAErnexa Therapeutics107.67 million7.33 millionNo DataPHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataSLRXSalarius Pharmaceuticals20510,000504,000Not OptionableTLPHTalphera1920.52 million19.87 millionOptionableSLRX, TLPH, ERNA, and PHXM HeadlinesRecent News About These CompaniesCorMedix makes $5M minority equity investment in TalpheraSeptember 9 at 2:34 PM | msn.comTalphera, Inc. (NASDAQ:TLPH) Sees Significant Drop in Short InterestSeptember 9 at 2:59 AM | americanbankingnews.comCorMedix Announces Strategic Minority Investment in TalpheraSeptember 8 at 8:30 AM | globenewswire.comTalphera, Inc. Earnings Call Highlights Strategic ProgressAugust 31, 2025 | tipranks.comTalphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trialAugust 27, 2025 | finance.yahoo.comTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialAugust 25, 2025 | prnewswire.comTalphera, Inc. (NASDAQ:TLPH) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | insidermonkey.comTalphera, Inc.: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.deTalphera Cuts Expenses 14 PercentAugust 15, 2025 | aol.comATalphera Reports Q2 2025 Financial Results and Study ProgressAugust 14, 2025 | tipranks.comTalphera, Inc. (TLPH) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comTalphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19MAugust 14, 2025 | msn.comTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | prnewswire.comA Preview Of Talphera's EarningsAugust 13, 2025 | benzinga.comTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025August 7, 2025 | prnewswire.comtalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesChevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Gold’s Explosive Rally: GDX ETF May Be the Fast Track to ProfitsBy Jeffrey Neal Johnson | September 4, 2025SLRX, TLPH, ERNA, and PHXM Company DescriptionsErnexa Therapeutics NASDAQ:ERNA$1.31 +0.05 (+3.56%) As of 01:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 09/8/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Salarius Pharmaceuticals NASDAQ:SLRX$4.64 +0.01 (+0.11%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Talphera NASDAQ:TLPH$0.84 -0.02 (-2.11%) As of 01:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
